XML 104 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue related to Sanofi agreement:
Total		$ 110,701	$ 118,192	$ 102,428
Novartis Institutes for BioMedical Research, Inc.
Revenue related to Sanofi agreement:
Total		37,944	5,252	0
Novartis Institutes for BioMedical Research, Inc. | Recognition of license and stand-ready fee
Revenue related to Sanofi agreement:
Total		29,945	4,143	0
Novartis Institutes for BioMedical Research, Inc. | Research services
Revenue related to Sanofi agreement:
Total		7,999	1,109	0
Biogen MA, Inc.
Revenue related to Sanofi agreement:
Total		42,300	27,901	0
Biogen MA, Inc. | Recognition of license and stand-ready fee
Revenue related to Sanofi agreement:
Total		29,224	21,356	0
Biogen MA, Inc. | Research services
Revenue related to Sanofi agreement:
Total		13,076	6,545	0
Kite Pharma, Inc.
Revenue related to Sanofi agreement:
Total		25,453	28,608	34,350
Kite Pharma, Inc. | Recognition of license and stand-ready fee
Revenue related to Sanofi agreement:
Total		24,977	25,046	24,977
Kite Pharma, Inc. | Research services
Revenue related to Sanofi agreement:
Total		476	3,562	9,373
Pfizer, Giroctocogene Fitelparvovec
Revenue related to Sanofi agreement:
Total		0	34,449	39,359
Pfizer, Giroctocogene Fitelparvovec | Recognition of license and stand-ready fee
Revenue related to Sanofi agreement:
Total	$ 8,700	0	3,111	15,697
Pfizer, Giroctocogene Fitelparvovec | Milestone achievement
Revenue related to Sanofi agreement:
Total		0	31,338	23,662
Pfizer C9ORF72
Revenue related to Sanofi agreement:
Total		0	12,985	1,827
Pfizer C9ORF72 | Recognition of license and stand-ready fee
Revenue related to Sanofi agreement:
Total		0	7,985	1,827
Pfizer C9ORF72 | Milestone achievement
Revenue related to Sanofi agreement:
Total		0	5,000	0
Sanofi S.A.
Revenue related to Sanofi agreement:
Total		3,114	5,322	22,680
Sanofi S.A. | Recognition of license and stand-ready fee
Revenue related to Sanofi agreement:
Total		34	298	3,494
Sanofi S.A. | Research services
Revenue related to Sanofi agreement:
Total		3,057	4,823	6,367
Sanofi S.A. | Milestone achievement
Revenue related to Sanofi agreement:
Total		$ 23	$ 201	$ 12,819

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: